AAV-ABCD1 Vector Constructs for ALD Gene Delivery and VLCFA Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for X-linked adrenoleukodystrophy (X-ALD) and adrenomyeloneuropathy (AMN), such as allogeneic hematopoietic stem cell transplant, are risky and time-consuming, and there is a need for safer and more efficient gene therapies using adeno-associated viruses (AAVs) that can deliver functional ABCD1 gene products to treat these conditions.
Innovation Solution
Development of improved AAV vectors, including rAAV vectors with specific nucleic acid sequences and capsids (AAV2, AAV9, AAVrh.10), administered via intrathecal or intracerebroventricular routes, to deliver the ABCD1 gene and produce functional ALDP protein, reducing VLCFA accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplant is used to treat X-ALD, then functional ALDP can be supplied to patients, but the treatment carries high risks including graft failure and graft versus host disease
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as an intermediary delivery system to transport the functional ABCD1 gene into patient cells. This viral vector mediator enables gene delivery without requiring allogeneic stem cell transplantation, thereby avoiding graft failure and graft versus host disease risks while still achieving functional ALDP production in the patient's own cells
Solution Approach 2:
The gene therapy approach enables patients' own cells to produce functional ALDP protein through delivery of the functional ABCD1 gene. Rather than relying on donor stem cells, the patient's cells are transformed into self-sufficient producers of the missing functional protein, eliminating the need for ongoing donor cell dependence
2Reliability
If allogeneic stem cell transplant is performed early to prevent disease progression, then treatment effectiveness improves, but the time required to find matched donors and perform transplantation increases to 12-18 months
Solution Approach 1:
The AAV vector system is prepared and characterized in advance, allowing for rapid deployment once a patient is diagnosed. The viral vectors can be manufactured and ready for administration without requiring the extensive 12-18 month donor matching and transplantation preparation timeline, enabling immediate treatment initiation to prevent disease progression
Solution Approach 2:
The patent changes the fundamental treatment parameter from allogeneic cell transplantation to autologous gene delivery. This parameter change eliminates the time-consuming donor matching process while maintaining treatment effectiveness, reducing the lead time from 12-18 months to a much shorter gene therapy administration timeline
3Productivity
If improved AAV vectors are designed with specific nucleic acid sequences and capsids to enhance delivery, then gene delivery efficiency improves, but the vector design and production complexity increases
Solution Approach 1:
The AAV vector system is divided into distinct functional segments: specific nucleic acid sequences (including ITRs and gene expression cassettes) and specific capsid proteins (AAV2, AAV9, AAVrh.10). This segmentation allows each component to be optimized independently for delivery efficiency while maintaining modular construction that manages overall system complexity
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3C
AI summary
The present disclosure generally relates to polynucleotides and AAV vectors that provide for the expression of ALD protein in target (e.g., neurons or glial) cells when administered to subjects in need thereof. The present disclosure further relates to compositions comprising such a polynucleotide or vector. These polynucleotides, vectors, and compositions may be used for the treatment and prevention of ALD or AMN in subjects in need thereof.